<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253262</url>
  </required_header>
  <id_info>
    <org_study_id>BrUOG 360</org_study_id>
    <nct_id>NCT04253262</nct_id>
  </id_info>
  <brief_title>A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer</brief_title>
  <official_title>A Phase Ib/II Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Miriam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clovis Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm Phase Ib/II, open label, safety, pharmacokinetic and efficacy clinical&#xD;
      study in adult patients with metastatic castration-resistant prostate cancer (mCRPC).&#xD;
      Patients will be treated with the combination of copanlisib and rucaparib for as long as the&#xD;
      patient does not have clinically significant progressive disease and/or unacceptable toxicity&#xD;
      and/or as long as the investigator deems that the patient is benefiting from treatment.&#xD;
      Treatment may also be stopped if the patient withdraws consent, or study termination occurs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2020</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Actual">July 14, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation will follow the standard 3+3 design. Once the maximum tolerated dose is achieved in Phase I, Phase II will proceed.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Cycle 1 (each cycle is 28 days) through pre-dosing cycle 2, approximately 1 month.</time_frame>
    <description>To evaluate the maximum tolerated dose of copanlisib with rucaparib in patients with metastatic castration-resistant prostate cancer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response</measure>
    <time_frame>Every 28 days on treatment, then every 3 months until progression of disease up to 3 years.</time_frame>
    <description>To estimate the overall response rate of the combination of copanlisib and rucaparib in patients with metastatic castration-resistant prostate cancer.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Level -2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg Rucaparib, 45 mg (day 1 &amp; 15) Copanlisib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg Rucaparib, 45 mg (day 1 &amp; 15) Copanlisib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg Rucaparib, 45 mg Copanlisib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg Rucaparib, 45 mg Copanlisib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg Rucaparib, 45 mg Copanlisib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg Rucaparib, 60 mg Copanlisib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rucaparib</intervention_name>
    <description>Rucaparib (PO twice daily continuous)</description>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_label>Dose Level -2</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <other_name>Rubraca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copanlisib</intervention_name>
    <description>Copanlisib (IV day 1, 8, 15; 28 day cycle)</description>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_label>Dose Level -2</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <other_name>Aliqopa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2&#xD;
&#xD;
          3. Life expectancy of at least 3 months&#xD;
&#xD;
          4. Histologically confirmed prostate cancer. Treatment-emergent small cell/NEPC&#xD;
             (neuroendocrine prostate cancer) is allowed, but de novo small cell carcinoma of the&#xD;
             prostate is excluded.&#xD;
&#xD;
          5. Progressive metastatic prostate cancer despite castrate levels of testosterone (&lt; 50&#xD;
             ng/dL).&#xD;
&#xD;
          6. Patients may have either non-measurable disease OR measurable disease (by RECIST&#xD;
             criteria)&#xD;
&#xD;
          7. Progressive disease during treatment (or within 4 weeks of completion) with&#xD;
             abiraterone, enzalutamide, and/or apalutamide based on any one of the following:&#xD;
&#xD;
               -  For patients with measurable disease, progression by the RECIST 1.1 criteria&#xD;
&#xD;
               -  PSA evidence for progressive prostate cancer consists of a PSA level of at least&#xD;
                  2 ng/ml which has risen on at least 2 successive occasions, at least one week&#xD;
                  apart. If the confirmatory PSA value is less than the screening PSA value, then&#xD;
                  an additional test for rising PSA will be required to document progression for&#xD;
                  the purposes of eligibility&#xD;
&#xD;
               -  Radionuclide bone scan: At least two new foci consistent with metastatic lesions&#xD;
&#xD;
          8. Testosterone &lt; 50 ng/dL. Patients must continue primary androgen deprivation with an&#xD;
             LHRH analogue if they have not undergone bilateral orchiectomy.&#xD;
&#xD;
          9. Prior therapy with taxane in the castrate-sensitive or castration-resistant settings&#xD;
             will be allowed. Prior treatment with radium-223 or sipuleucel-T is permitted, but not&#xD;
             required.&#xD;
&#xD;
         10. No other systemic therapies for prostate cancer within 21 days prior to cycle 1 day 1&#xD;
             of study therapy or 5 half-lives, whichever is shorter, prior to day 1 of study&#xD;
             therapy.&#xD;
&#xD;
         11. Left ventricular ejection fraction (LVEF) ≥ 50% as determined by Multiple Gated&#xD;
             acquisition (MUGA) scan or echocardiogram (ECHO) obtained during screening&#xD;
&#xD;
         12. Patients must have adequate organ and bone marrow function within 14 days of inclusion&#xD;
             in the study as defined below:&#xD;
&#xD;
               -  Absolute Neutrophil Count ≥ 1,500/mm3&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               -  Platelets ≥ 100,000 /mm3&#xD;
&#xD;
               -  PT/INR ≤ 1.5 x ULN unless on chronic and stable anticoagulation at time of study&#xD;
                  entry&#xD;
&#xD;
               -  Bilirubin ≤1.5 x institutional upper limit of normal (ULN) except for&#xD;
                  unconjugated hyperbilirubinemia or Gilbert's Syndrome, who can have total&#xD;
                  bilirubin &lt;3.0 mg/dL&#xD;
&#xD;
               -  AST/ALT ≤ 3 x ULN (≤ 5 x ULN if liver metastases present)&#xD;
&#xD;
               -  Lipase ≤ 1.5 x ULN&#xD;
&#xD;
               -  HbA1c &lt; 8.5 %&#xD;
&#xD;
               -  Serum Creatinine ≤ 1.5 X ULN (upper limit of normal) or creatinine clearance ≥ 45&#xD;
                  mL/minute (using Cockcroft/Gault formula)&#xD;
&#xD;
         13. Sexually active males must use a condom with spermicide during intercourse while&#xD;
             taking the drug and for 6 months after stopping treatment, even if patient is&#xD;
             vasectomized to prevent delivery of the drug via seminal fluid.&#xD;
&#xD;
         14. Patients must agree to provide tumor tissue, either fresh or archival specimen of&#xD;
             primary tumor and/or metastatic lesion, if available. Availability of tissue will not&#xD;
             be required for enrollment.&#xD;
&#xD;
         15. Subjects must have the ability to understand and the willingness to sign a written&#xD;
             informed consent prior to registration on study. Subjects should be willing and able&#xD;
             to comply with the protocol for the duration of the study including undergoing&#xD;
             treatment and scheduled visits and examinations at the institution.&#xD;
&#xD;
         16. Only during phase 2, patients will be required to have mutations in DNA repair genes&#xD;
             based on molecular tests performed on germline DNA, prostate cancer tissue or ctDNA.&#xD;
             Qualifying mutations (i.e. deleterious/pathogenic alterations) in at least one of the&#xD;
             following genes involved with homologous recombination repair will be required: BRCA1,&#xD;
             BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, FANCL, FANCA, PALB2, PPP2R2A, RAD51B, RAD51C,&#xD;
             RAD51D, and RAD54L. Variants of unknown significance in one of the above genes are not&#xD;
             eligible.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. History of myelodysplastic syndrome or acute myeloid leukemia.&#xD;
&#xD;
          2. During phase 2, patients must not have received previous treatment with a DNA-damaging&#xD;
             cytotoxic chemotherapy (e.g. prior platinum-based chemotherapy and mitoxantrone are&#xD;
             not permitted) or PARP inhibitor. Prior treatment with PARP inhibitor is allowed&#xD;
             during phase I dose escalation.&#xD;
&#xD;
          3. Untreated leptomeningeal or metastatic CNS disease; patients with treated disease may&#xD;
             be eligible if clinically stable for 4 weeks after radiation or surgery including&#xD;
             those with history of spinal cord compression that have received definitive treatment.&#xD;
             If patients are receiving steroids as adjunct for treatment of leptomeningeal disease&#xD;
             or metastatic CNS disease, dose should be stable for 4 weeks prior to day 1 of cycle&#xD;
             1.&#xD;
&#xD;
          4. Clinically significant, uncontrolled heart disease and/or recent events including any&#xD;
             of the following:&#xD;
&#xD;
               -  History of acute coronary syndromes (including myocardial infarction, unstable&#xD;
                  angina, coronary artery bypass grafting, coronary angioplasty or stenting) or&#xD;
                  symptomatic pericarditis within 6 months prior to screening&#xD;
&#xD;
               -  History of documented congestive heart failure (New York Heart Association&#xD;
                  functional classification III-IV)&#xD;
&#xD;
               -  History of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal&#xD;
                  arrhythmias, or conduction abnormality within 12 months of screening. Patients&#xD;
                  with rate-controlled atrial fibrillation or flutter are permitted.&#xD;
&#xD;
               -  QTcF &gt; 470 msec on screening 12-lead ECG&#xD;
&#xD;
               -  Documented cardiomyopathy&#xD;
&#xD;
          5. Clinically significant uncontrolled hypertension (systolic blood pressure &gt; 150 mmHg&#xD;
             or diastolic pressure &gt; 90 mmHg despite optimal medical management). For the purpose&#xD;
             of this protocol definition of uncontrolled hypertension is based on persistent (≥72&#xD;
             hours) and symptomatic.&#xD;
&#xD;
          6. Arterial or venous thrombotic or embolic events such as cerebrovascular accident&#xD;
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism&#xD;
             within 6 months before the start of study medication. However, patients with a venous&#xD;
             thrombosis, including a pulmonary embolus, who have been on stable anticoagulation&#xD;
             (more than 1 month without bleeding on a stable dose) is permitted. Patients with&#xD;
             evidence or history of uncontrolled bleeding diathesis. Any hemorrhage or bleeding&#xD;
             event ≥ CTCAE Grade 3 within 4 weeks prior to the start of study medication&#xD;
&#xD;
          7. History or concurrent condition of clinically significant interstitial lung disease&#xD;
             and/or severely impaired lung function. History of renal failure requiring peritoneal&#xD;
             dialysis or hemodialysis. History of cirrhosis Child-Pugh B or C. Intestinal&#xD;
             malabsorption.&#xD;
&#xD;
          8. Active, clinically serious infections of CTCAE (v 5.0) Grade ≥ 2 or per investigator&#xD;
             discretion.&#xD;
&#xD;
          9. History of uncontrolled human immunodeficiency virus (HIV) infection defined as CD4 &lt;&#xD;
             200 cells/mm3 or detectable viral load is not allowed.&#xD;
&#xD;
         10. Hepatitis B (HBV) or hepatitis C (HCV). All patients must be screened for HBV and HCV&#xD;
             up to 28 days prior to study drug start using the routine hepatitis virus laboratorial&#xD;
             panel. Patients positive for HBsAg or HBcAb will be eligible if they are negative for&#xD;
             HBV-DNA. These patients should receive prophylactic antiviral therapy. Patients&#xD;
             positive for anti-HCV antibody will be eligible if they are negative for HCV-RNA.&#xD;
&#xD;
         11. Previous or concurrent history of malignancies within 5 years prior to study treatment&#xD;
             except for curatively treated cervical carcinoma in situ, non-melanoma skin cancer,&#xD;
             superficial bladder cancer (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1&#xD;
             [tumor invades lamina propria]) or other T1 tumor that has been surgically removed&#xD;
             with a low chance of recurrence in the next 3 years.&#xD;
&#xD;
         12. Known hypersensitivity to any of the test drugs, test drug classes, or excipients in&#xD;
             the formulation&#xD;
&#xD;
         13. Ongoing substance abuse, medical, psychological or social conditions that may&#xD;
             interfere with the patient's participation in the study or evaluation of the study&#xD;
             results.&#xD;
&#xD;
         14. Prior radiation within 7 days of start drug. Prior major surgery, open biopsy or&#xD;
             significant trauma within 28 days of start drug.&#xD;
&#xD;
         15. Patients with severe psychiatric illness/social situations that would limit compliance&#xD;
             with study requirements in the judgment of study investigator&#xD;
&#xD;
         16. Patient has a history of non-compliance to medical regimen or inability to grant&#xD;
             consent&#xD;
&#xD;
         17. Ongoing immunosuppressive therapy. Patients may be receiving up to 10mg/day of&#xD;
             prednisone.&#xD;
&#xD;
         18. Radiotherapy or immuno-/chemotherapy less than 2 weeks before start of treatment. A&#xD;
             wash-out period of 2 months from radiopharmaceuticals such as radium-223 and&#xD;
             177Lu-PSMA among others will be required.&#xD;
&#xD;
         19. Myeloid growth factors within 14 days prior to treatment.&#xD;
&#xD;
         20. Blood or platelet transfusion less than 7 days before cycle 1 day 1.&#xD;
&#xD;
         21. History of having received an allogeneic bone marrow or organ transplant.&#xD;
&#xD;
         22. Major surgical procedure or significant traumatic injury (as judged by the&#xD;
             investigator) within 28 days before start of treatment, or have not recovered from&#xD;
             major side effects; open biopsy within 7 days before start of treatment.&#xD;
&#xD;
         23. Anti-arrhythmic therapy for ventricular arrhythmias. Use of amiodarone and propafenone&#xD;
             for atrial fibrillation rate control is allowed.&#xD;
&#xD;
         24. Use of CYP3A4 inhibitors and inducers. Copanlisib is primarily metabolized by CYP3A4.&#xD;
             Therefore concomitant use of strong inhibitors of CYP3A4 (e.g., ketoconazole,&#xD;
             itraconazole, clarithromycin, darunavir, indinavir, lopinavir, mifepristone,&#xD;
             posaconazole, ombitasvir, idelalisib, cobicistat, atazanavir, ritonavir, indinavir,&#xD;
             nelfinavir and saquinavir) and inducers (apalutamide, carbamazepine, enzalutamide,&#xD;
             fosphenytoin, phenobarbital, phenytoin, primidone, rifampin) is not allowed. Rucaparib&#xD;
             is a moderate inhibitor of CYP1A2 and a weak inhibitor of CYP2C9, CYP2C19 and CYP3A4&#xD;
             and no specific medications is contra-indicated but dose adjustment may be necessary&#xD;
             of concurrent medication&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedito Carneiro, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BrUOG</last_name>
    <phone>401-863-3000</phone>
    <email>BrUOG@brown.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helen Diller Family Comprehensive Cancer Center University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BrUOG</last_name>
      <phone>401-863-3000</phone>
      <email>BrUOG@Brown.edu</email>
    </contact>
    <investigator>
      <last_name>Rahul Aggarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lifespan Cancer Institute</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BrUOG</last_name>
      <phone>401-863-3000</phone>
      <email>BrUOG@brown.edu</email>
    </contact>
    <investigator>
      <last_name>Benedito Carneiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>Benedito A Carneiro, MD</investigator_full_name>
    <investigator_title>Principal Investigator: Sponsor-Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rucaparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

